IMMURON
IMRN Healthcare Biotechnology
IMMURON’s revenue for fiscal 2026 (year ended June 2026) was $5.2 million, up 10.9% from fiscal 2025. Revenue growth for five consecutive years.
Follow IMRN
IMMURON (IMRN) EV/Sales
As of 16 October 2026, IMMURON (IMRN) trades at a EV/Sales of −3.5×. Over the past ten years it has ranged from −24.7× (December 2022) to 0.0× (June 2020); the current reading is higher than 52% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | −3.5× | — |
| FY2025 | −1.0× | — |
| FY2024 | −4.4× | — |
| FY2023 | −7.3× | — |
| FY2022 | −24.7× | — |
| FY2021 | −10.0× | — |
| FY2020 | −0.6× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | −0.7× | — |
| Dec 2022 | 0.0× | — |
| Jun 2022 | −5.8× | — |
| Dec 2021 | −2.5× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IMRN IMMURON | −3.5× |
| QNRX Quoin Pharmaceuticals, Ltd. Sponsored ADR compare | n/m |
| ADIL Adial Pharmaceuticals, Inc. compare | n/m |
| NKGN NKGen Biotech, Inc. compare | n/m |
| CSCIF COSCIENS Biopharma Inc. compare | 0.2× |
| SNTI Senti Biosciences, Inc. compare | 0.3× |
| XTLB XTL Biopharmaceuticals Ltd. compare | 1.3× |
| KPTI Karyopharm Therapeutics Inc. compare | 1.3× |
| BOLT Bolt Biotherapeutics, Inc. compare | 1.6× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)